Roche, angling for third place among companies in the growing field of immuno-oncology, is touting promising early data for its so-called checkpoint inhibitor in skin cancer, building its case for the wide use of its in-development therapy.
William Scully, one of two owners of Medical Device King based in New York, was convicted on charges that he sold more than $17 million worth of fake or unapproved drugs that were manufactured overseas.
A court in New Delhi has given permission for the Drug Controller General of India to process the application by Reliance Life Sciences for a breast cancer drug package.
The drug pricing debate is heating up stateside, but across the pond, it's been hot for some time. Adding fuel to the fire--about Roche's breast cancer med Kadcyla, at least--U.K. cost-effectiveness gatekeepers gave a final thumbs-down to the drug, two weeks after England's special oncology drugs fund agreed to cover the med at a discount.
Roche's Genentech is pairing up with Novartis to split the ex-U.S. rights to an Ophthotech eye drug, opting into an agreement that could be worth more than $1 billion.
As drug-resistant superbug infections continue to rise, diagnostics companies are rolling out rapid, point-of-care devices that can quickly identify infectious bacteria and potentially cut down on the need for unnecessary antibiotics, cashing in on a growing market for the tools.
Roche will close four plants around the world and lay off 1,200 people as it moves to new technology for manufacturing small molecule drugs. It says it will build a late-stage technical development and launch facility in Switzerland for targeted, high-potency drugs.
Roche will close four plants and lay off 1,200 people as it moves toward more biologics and new specialized small-molecule drugs require less capacity. The drugmaker will take a $1.6 billion charge to cover the move as it plays out over the next 5 years.
Amgen may have pulled off a pay-for-performance pricing deal on its pricey new cholesterol drug Repatha with Boston-based Harvard Pilgrim. But other outcomes-based pricing negotiations haven't been as successful, and there are major reasons why.
When Novartis bought GlaxoSmithKline's oncology business, the newest products were a pair of targeted melanoma drugs, Taflinlar and Mekinist. The two meds had racked up trial data showing they beat Roche's own targeted drug Zelboraf when used in tandem.